跳至主要内容
临床试验/NL-OMON56981
NL-OMON56981尚未招募不适用

An exploratory study to evaluate in vivo, ex vivo and clinical hypersensitivity reactions after first-time treatment with complement-reactogenic infusions - In vivo and ex vivo complement activation

Centre for Human Drug Research0 个研究点目标入组 60 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
尚未招募
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Patients who have an indication for receiving potentially complement
  • reactogenic treatments (e.g. paclitaxel or liposomal doxorubicin (Caelyx))
  • according to their clinical treatment protocol as prescribed by their treating
  • medical specialist. Patients eligible for participation may include, but will
  • not be limited to, patients with breast cancer or ovarian cancer.
  • 2. Able and willing to give written informed consent and to comply with the
  • study restrictions.
  • 3. Has the ability to communicate well with the Investigator in the Dutch or
  • English language and willing to comply with the study restrictions.

排除标准

  • 1. Previous treatment with same complement reactogenic treatment (e.g.
  • paclitaxel or liposomal doxorubicin (Caelyx) (e.g. in case of reintroduction)
  • 2. Subjects with poor venous access limiting phlebotomy.
  • 3. Patients with known complement deficiencies.
  • 4. Patients who received plasma infusions within a week of the first infusion
  • 5. Any condition that would, in the opinion of the investigator, potentially
  • compromise the safety of the patient or may preclude the patient*s successful
  • completion of the clinical trial.
  • 6. Patients receiving chemotherapeutic combination therapy during the study
  • period (first treatment day).

研究者

相似试验